Analysts’ Weekly Ratings Updates for Alkermes (ALKS)

Several brokerages have updated their recommendations and price targets on shares of Alkermes (NASDAQ: ALKS) in the last few weeks:

• 11/4/2026 – Alkermes had its price target raised by Wells Fargo & Company from $65.00 to $68.00. They now have an “overweight” rating on the stock.
• 11/4/2026 – Alkermes was given a new $61.00 price target by Robert W. Baird.
• 11/4/2026 – Alkermes had its price target raised by Royal Bank Of Canada from $56.00 to $57.00. They now have an “outperform” rating on the stock.
• 11/4/2026 – Alkermes had its price target raised by HC Wainwright from $43.00 to $50.00. They now have a “neutral” rating on the stock.
• 10/16/2026 – Alkermes is now covered by Truist Financial. They set a “buy” rating and a $55.00 price target on the stock.
• 9/24/2026 – Alkermes is now covered by The Goldman Sachs Group. They set a “neutral” rating and a $50.00 price target on the stock.
• 9/24/2026 – Alkermes is now covered by The Goldman Sachs Group. They set a “hold” rating and a $50.00 price target on the stock.
• 9/22/2026 – Alkermes had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $56.00 price target on the stock.
• 9/22/2026 – Alkermes had its price target raised by Robert W. Baird from $58.00 to $61.00. They now have an “outperform” rating on the stock.
• 9/21/2026 – Alkermes had its “neutral” rating reaffirmed by HC Wainwright.
• 9/21/2026 – Alkermes had its “buy” rating reaffirmed by TD Cowen.
• 9/21/2026 – Alkermes had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $62.00 price target on the stock.
• 9/16/2026 – Alkermes was upgraded by Mizuho to “strong-buy”.

Alkermes Stock Up 0.4%

Shares of NASDAQ:ALKS traded up $0.20 on Wednesday, reaching $45.89. The company had a trading volume of 2,179,041 shares, compared to its average volume of 2,129,330. Alkermes plc has a twelve month low of $27.00 and a twelve month high of $55.67. The stock has a 50-day moving average price of $43.92 and a 200 day moving average price of $40.59. The stock has a market capitalization of $7.70 billion, a P/E ratio of 120.77 and a beta of 0.32. The company has a quick ratio of 1.85, a current ratio of 2.30 and a debt-to-equity ratio of 0.82.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Tuesday, November 3rd. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.17. Alkermes had a return on equity of 4.15% and a net margin of 3.96%. The company had revenue of $480.13 million during the quarter, compared to the consensus estimate of $463.48 million. During the same quarter in the prior year, the company posted $0.49 EPS. The firm’s revenue was up 21.8% on a year-over-year basis. On average, equities analysts expect that Alkermes plc will post -0.57 EPS for the current year.

Insider Buying and Selling

In related news, EVP Craig C. Hopkinson sold 9,000 shares of Alkermes stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $46.99, for a total value of $422,910.00. Following the transaction, the executive vice president owned 65,389 shares in the company, valued at $3,072,629.11. This trade represents a 12.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christian Nichols sold 7,576 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $49.23, for a total transaction of $372,966.48. Following the transaction, the senior vice president directly owned 102,193 shares of the company’s stock, valued at approximately $5,030,961.39. This represents a 6.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 22,679 shares of company stock worth $1,070,940 in the last quarter. 4.59% of the stock is currently owned by company insiders.

Alkermes plc (NASDAQ:ALKS) is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases. Its research and development activities address conditions including schizophrenia, bipolar disorder, addiction, depression and other neuropsychiatric disorders.

The company’s marketed products include Vivitrol, an extended-release injectable form of naltrexone used to treat alcohol dependence and prevent relapse to opioid dependence; Aristada and Aristada Initio, long-acting injectable formulations of aripiprazole lauroxil for the treatment of schizophrenia; and Lybalvi, a combination of olanzapine and samidorphan approved for schizophrenia and bipolar I disorder in adults.

Founded in 1987, Alkermes is incorporated in Ireland and maintains its corporate headquarters in Waltham, Massachusetts.